Exciting News from Our Cardiovascular Practice!

Dr. Dinesh Arab and his team are thrilled to announce the integration of clinical trials alongside their established cardiovascular practice. With over 20 years of experience in clinical research, Dr. Arab became the Owner of Cardiology Research in 2023.

What This Means for Our Patients:

  • Cutting-Edge Therapies: Clinical research trials provide our patients with access to innovative therapies for various cardiology indications that may not be available through standard treatment options.
  • Expert Team: Dr. Arab is joined by esteemed colleagues Dr. Rene Celis and Dr. Nathan Valin, who are also heavily involved in advancing cardiology research.

We are committed to offering our patients the latest advancements in cardiovascular care and are excited about the possibilities these clinical trials present.

If you have any questions or would like more information about participating in a clinical trial, please feel free to reach out! 386-310-7462

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants with Elevated Lipoprotein(a)

A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40%

A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) ≥40%

A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease

Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation

A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation